Amylyx Pharmaceuticals, Inc. balance sheet AMLX

Annual Quarterly

As of Sep 30, 2026, Amylyx Pharmaceuticals, Inc. had total assets of $786.8 million and total liabilities of $33.1 million. Total assets were up 116.9% from a year earlier. Stockholders' equity was $753.7 million. It held $768.1 million in cash and investments against $4.9 million of total debt, net cash of $763.2 million. The current ratio, current assets divided by current liabilities, was 26.81.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	240 +6.6%	49 -15.1%	229 +283.4%	227 +192.9%	225 +213.4%	58 -22.6%	60 -65.0%	77 -54.5%
Short-term investments	528 +344.4%	201 +64.1%	51 -64.9%	90 -8.9%	119 -26.9%	123 -47.7%	144 -28.8%	99 -50.7%
Cash and investments	768 +123.3%	251 +38.7%	280 +37.1%	317 +79.6%	344 +46.8%	181 -41.6%	204 -45.3%	177 -52.5%
Receivables	—	—	—	0 -80.3%	0 -92.4%	0 -97.5%	0 -98.5%	0 -98.9%
Total current assets	779 +120.4%	256 +37.2%	285 +31.9%	324 +70.9%	353 +44.1%	187 -42.8%	216 -47.4%	189 -59.2%
Property and equipment, net	0 -52.1%	0 -55.3%	0 -74.0%	0 -67.7%	0 -68.1%	0 -69.8%	1 -66.8%	1 -64.2%
Total assets	787 +116.9%	265 +36.0%	294 +33.7%	333 +71.8%	363 +44.7%	195 -41.4%	220 -47.4%	194 -62.6%
Liabilities and equity
Accounts payable	5 -10.0%	6 +68.0%	4 -26.6%	4 +19.7%	5 +259.0%	3 -33.5%	5 -77.6%	3 -86.7%
Total current liabilities	29 +12.6%	21 -1.3%	16 -11.0%	23 -20.1%	26 -52.2%	21 -69.4%	18 -80.4%	28 -65.4%
Total liabilities	33 +7.5%	25 -5.0%	20 +12.0%	27 -5.1%	31 -43.6%	27 -62.3%	18 -80.4%	29 -65.6%
Stockholders' equity	754 +127.0%	239 +42.5%	273 +35.6%	305 +85.3%	332 +69.2%	168 -35.8%	201 -37.9%	165 -62.0%
Debt
Lease liabilities	5 -3.1%	5 -11.9%	6 +307.5%	6 +200.7%	6 +131.2%	6 +89.8%	1 -62.6%	2 -53.2%
Total debt	5 -3.1%	5 -11.9%	6 +307.5%	6 +200.7%	6 +131.2%	6 +89.8%	1 -62.6%	2 -53.2%
Net cash	763 +125.2%	246 +40.4%	274 +35.3%	311 +78.2%	338 +45.8%	175 -43.0%	203 -45.2%	175 -52.5%
Ratios
Current ratio	26.81x	12.12x	17.85x	14.27x	13.70x	8.72x	12.05x	6.67x
Debt to equity	0.01x	0.02x	0.02x	0.02x	0.02x	0.04x	0.01x	0.01x
Return on equity	-21.65%	-63.59%	-54.95%	-47.41%	-44.96%	-111.75%	-108.66%	-183.14%
Return on assets	-20.74%	-57.49%	-51.13%	-43.51%	-41.15%	-96.40%	-99.63%	-155.83%
Book value per share	5.86	2.15	2.46	2.78	3.02	1.88	2.26	2.40

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: AMLX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Cambridge, MA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1658551

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.